Threshold of 26% for CD27+B cells as a predictor of tumor necrosis factor inhibitor response. (A) Association of CD27+ B-cell proportion ≥26% and <26% at baseline and Disease Activity Score in 28 joints (DAS28) after 3 months of tumor necrosis factor inhibitor (TNFi) therapy (P = 0.01). (B) Association of CD27+ B-cell proportion ≥26% at baseline and European League Against Rheumatism response (4.9 (1.3 to 18.6); P = 0.02). Each data point represents one participant. Horizontal bars are medians, and whiskers are IQR (25th to 75th percentile).